BriaCell Biotech Investor Presentation 2019 – Bria-OTS Cancer Immunotherapy

BriaCell is developing Bria-OTS™, a personalized off-the-shelf cancer immunotherapy targeting advanced breast cancer with a $1-5 billion market opportunity. The company has completed Phase I/IIa trials with excellent safety data and is initiating combination studies with Merck's Keytruda®, supported by experienced management with a track record of 10+ drug approvals.